Treatment of primary in metastatic prostate cancer: what is the standard of care?
AffiliationMinistry of HealthSri Lanka Cancer Research Group, Sri Lanka College of Oncologists, Colombo, Sri Lanka,
MetadataShow full item record
AbstractUntil recently, men with metastatic prostate cancer were commenced on androgen deprivation therapy at diagnosis, followed by sequential lines of treatment with the development of castration resistance. However, the results of recent clinical trials, which revealed that the addition of radiotherapy to the prostate to a dose of 55 to 60 Gy in 20 fractions over 4 weeks in patients with low-volume metastatic hormone-sensitive prostate cancer, in addition to androgen deprivation therapy and another systemic treatment option, either docetaxel, abiraterone, enzalutamide, or apalutamide, has led to a paradigm change in the management of this disease.
CitationJoseph N, Anjanappa M, Choudhury A. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care? Cancer J. 2020;26(1):83-6.
- Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
- Authors: Kinsey EN, Zhang T, Armstrong AJ
- Issue date: 2020 Jan/Feb
- SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
- Authors: González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA
- Issue date: 2021 May
- Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
- Authors: Damodaran S, Lang JM, Jarrard DF
- Issue date: 2019 May
- Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
- Authors: Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J
- Issue date: 2015 Aug
- Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
- Authors: Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y
- Issue date: 2015 Aug